Indian company Hetero pulls heart drug from US amid cancer risk probes

At least a dozen companies around the world have pulled specific batches of valsartan from the market since early July, when regulators said valsartan made by the Chinese supplier Zhejiang Huahai Pharmaceuticals had been found to contain a probable human carcinogen

from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/2P0JFde

Newer Post Older Post